# ClinicalTrials.gov record NCT04575844

> PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04575844-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04575844-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04575844-liraglutide-v1.json
- Content SHA-256: `bc296532440de50d7a029fbbd7f54bbf9953521b354a6f00bdee505313fbc892`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04575844 ([`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`](#source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`](#source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`](#source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`](#source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b))

## Sources

<a id="source-ctg-observation-nct04575844-2026-05-06-d301f90b0d5b"></a>
- **ClinicalTrials.gov record NCT04575844 · retained source version 2026-05-06:d301f90b0d5be92254aa2e6906ecb93e099fc1c8c96ed61c93b1ff7ba0bc9943** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04575844) (`ctg-observation-nct04575844-2026-05-06-d301f90b0d5b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04575844." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04575844-liraglutide-v1.json SHA-256: bc296532440de50d7a029fbbd7f54bbf9953521b354a6f00bdee505313fbc892.